All In Biotech

Drug Trial Radar · NCT06385795

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

A Phase 2a, 4-Week, Single Arm, Open-label, Multi-center Study to Assess Safety, Tolerability, and Preliminary Efficacy of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 22, 2024

Primary completion

Aug 13, 2025

Study completion Aug 13, 2025

Sponsor

Lead sponsor
Noema Pharma AGIndustry
Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 45 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.

Conditions

  • Menopause Syndrome
  • Menopause
  • Hot Flashes

Interventions

  • NOE-115Drug

    NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Withdrawals Due to Adverse Events While on NOE-115 for Any ReasonTime frame: 4 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Noema PMM-201 Site #104

    San Diego, California

  • Noema PMM-201 Site #102

    Jacksonville, Florida

  • Noema PMM-201 Site #101

    Atlanta, Georgia

  • Noema PMM-201 Site #106

    Las Vegas, Nevada

  • Noema PMM-201 Site #103

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.